Dual-Chamber Physiologic-Cost Modeling for Minimally Invasive Thoracolumbar Reconstruction in Hematologic-Fragility Hosts: A Conceptual Framework with an Illustrative Myelodysplastic Syndrome Case
Recent Advances in Clinical Trials · 28.02.2026 · 6 (1)
DOI: 10.33425/2771-9057.1077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Recent Advances in Clinical Trials, online erschienen am 28.02.2026. Verfasst von Chi-Ming Chiang.
Abstract (Originalsprache)
Background
Myelodysplastic syndromes (MDS) couple marrow failure with skeletal fragility, creating a narrow physiological margin for complex spine reconstruction. Conventional evaluations of minimally invasive surgery focus on aggregate blood loss, complications, and costs, but rarely partition the physiologic burden across organ-system domains that are critical in hematologic-fragility hosts.
Objective
To introduce a dual-chamber physiologic-cost model (DPCM) that decomposes total physiologic cost into chest-wall/lung and paraspinal-muscle domains, illustrate its application in a minimally invasive thoracolumbar reconstruction for MDS, and outline its extension toward decision-analytic modeling and multicenter evaluation.
Methods
We treated total physiologic cost (TPC) as the sum of chest-wall/lung burden (C_chest) and paraspinal-muscle burden (C_paraspinal). C_chest was proxied by chest-tube duration and 30-day pulmonary complications, whereas C_paraspinal was proxied by estimated blood loss, red-cell and platelet transfusions, 30-day surgical-site infection, and length of stay. These proxies were quantified in a late-elderly woman with transfusion-dependent MDS who underwent video-assisted thoracoscopic anterior decompression with autologous fibular strut reconstruction followed by percutaneous posterior fixation under restrictive transfusion thresholds. DPCM indices were compared qualitatively against published medians for open thoracotomy and open posterior exposures, as well as minimally invasive benchmarks.
Results
The hybrid thoracoscopic–percutaneous strategy achieved stable anterior column support and restored alignment with an estimated blood loss of 320 mL, 1 unit of red cells and 2 units of platelets transfused, 2 chest-tube days, and a 9-day hospital stay. No pulmonary or wound complications occurred within 30 days. Relative to historical open benchmarks, the DPCM indicated marked reductions in both C_chest and C_paraspinal, reflected by lower blood loss, transfusion exposure, chest-tube duration, and length of stay. The DPCM structure proved readily amenable to conceptual extension into a state-transition (Markov) decision model for long-term cost-effectiveness analysis.
Conclusions
In hematologic-fragility hosts such as MDS, a dual-chamber physiologic-cost framework makes explicit the organ-system trade-offs of access and fixation choices. The illustrative case suggests that thoracoscopic anterior reconstruction with autologous fibular strut and percutaneous posterior fixation can minimize physiologic cost while satisfying restrictive transfusion strategies. Embedding DPCM within a state-transition model provides a pathway for multicenter, model-based comparisons of minimally invasive versus open strategies in high-risk spine populations.
Zitieren
APA
Chiang, C. (2026). Dual-Chamber Physiologic-Cost Modeling for Minimally Invasive Thoracolumbar Reconstruction in Hematologic-Fragility Hosts: A Conceptual Framework with an Illustrative Myelodysplastic Syndrome Case. Recent Advances in Clinical Trials, 6(1). https://doi.org/10.33425/2771-9057.1077
Vancouver
Chiang C. Dual-Chamber Physiologic-Cost Modeling for Minimally Invasive Thoracolumbar Reconstruction in Hematologic-Fragility Hosts: A Conceptual Framework with an Illustrative Myelodysplastic Syndrome Case. Recent Advances in Clinical Trials. 2026;6(1). doi:10.33425/2771-9057.1077
BibTeX
@article{Chiang2026,
author = {Chiang, Chi-Ming},
title = {Dual-Chamber Physiologic-Cost Modeling for Minimally Invasive Thoracolumbar Reconstruction in Hematologic-Fragility Hosts: A Conceptual Framework with an Illustrative Myelodysplastic Syndrome Case},
journal = {Recent Advances in Clinical Trials},
year = {2026},
volume = {6},
number = {1},
doi = {10.33425/2771-9057.1077}
}
EUVIMED